Similar drugsTo uncover
Dosage form: & nbsppills
Composition:

1 the tablet contains:

active substance: nopept (ethyl ester of N-phenylacetyl-L-prolylglycine) -10 mg,

Excipients: potato starch - 13.5 mg, lactose monohydrate - 55 mg, microcrystalline cellulose - 21.2 mg, magnesium stearate - 0.3 mg, povidone - 0.0008 mg.

Description:

Tablets are white, round, flat-faced with a bevel.

Pharmacotherapeutic group:Nootropic remedy
ATX: & nbsp
  • Other psychostimulants and nootropic drugs
  • Pharmacodynamics:

    Hopept® has nootropic and neuroprotective properties. Improves learning ability and memory by acting on all processing phases: initial processing of information, consolidation, extraction. Prevents the development of amnesia caused by electric shock, blockade of central cholinergic structures, glutamatergic receptor systems, deprivation of the paradoxical phase of sleep.

    The neuroprotective (protective) action of Noopept® is manifested in increasing the resistance of brain tissue to damaging effects (trauma, hypoxia, electroconvulsive, toxic) and weakening the degree of damage to brain neurons. The drug reduces the volume of the focus on the thrombotic stroke model and prevents the death of neurons in the tissue culture of the cerebral cortex and cerebellum, subjected to the action of neurotoxic concentrations of glutamate, free radical oxygen.Noopept® has an antioxidant effect, blocks potential-dependent calcium channels of neurons, weakening the neurotoxic effect of excess calcium, improves the rheological properties of blood, possessing antiplatelet, fibrinolytic, anticoagulant properties.

    The nootropic effect of the drug is associated with the formation of cycloprolylglycine, similar in structure to the endogenous cyclic dipeptide, which has antiamnestic activity, as well as the presence of cholinopositive action.

    Noopept® increases the transcallosal response amplitude, facilitating associative connections between the cerebral hemispheres at the level of the cortical structures. Promotes the restoration of memory and other cognitive functions, disrupted as a result of damaging effects - brain trauma, local and global ischemia, prenatal injuries (alcohol, hypoxia).

    Therapeutic effect of the drug in patients with organic disorders central nervous system - the system manifests itself, starting from the 5th-7th day of treatment. Initially, the anxiolytic and light stimulating effects present in the spectrum of Noopept® activity are realized,manifested in the reduction or disappearance of anxiety, increased irritability, affective lability, sleep disturbances. After 14-20 days of therapy, the positive effect of the drug on cognitive functions, attention and memory parameters is revealed.

    Hopept® has a vegetative normalizing effect, it helps to reduce headaches, orthostatic disorders, tachycardia.

    With the withdrawal of the drug there is no syndrome of "withdrawal".

    Does not have a damaging effect on internal organs; does not lead to a change in the cellular composition of the blood and biochemical indicators of blood and urine; does not have an immunotoxic, teratogenic effect, does not show mutagenic properties.

    Pharmacokinetics:Ethyl N-phenylacetyl-L-prolylglycine, absorbed in the gastrointestinal tract unchanged, enters the systemic bloodstream, penetrates the blood-brain barrier, is detected in the brain at higher concentrations than in the blood. The time to reach the maximum concentration is 15 minutes on average. The half-life of blood plasma is 0.38 hours. It is partially preserved in an unchanged form, partially metabolized with the formation of phenylacetic acid,phenylacetylproline and cycloprolylglycine. Has a high relative bioavailability (99.7%), does not accumulate in the body, does not cause drug dependence.
    Indications:

    Impaired memory, attention, other cognitive functions and emotionally-labile disorders (including those in elderly patients) with:

    • consequences of traumatic brain injury,
    • postcommunism syndrome,
    • cardiovascular brain failure (encephalopathy of various origins),
    • asthenic disorders,
    • Other states with signs of a decline in intellectual productivity.

    Contraindications:

    Pregnancy, lactation. Age to 18 years. Hypersensitivity to the components of the drug. Deficiency of lactase, lactose intolerance, glucose-galactose malabsorption. Expressed violations of the liver and kidneys.

    Dosing and Administration:Hopept® is administered orally after eating. Treatment begins with a dose of 20 mg, divided into two doses of 10 mg during the day (morning and afternoon). If the therapy is ineffective and if the drug is well tolerated, the dose is increased to 30 mg (see "Special instructions"), distributing it to three 10 mg units throughout the day.Do not take the drug after 18 hours. The duration of the course treatment is 1.5-3 months. Repeated. the course of treatment can be carried out after 1 month if necessary.
    Side effects:

    Allergic reactions are possible. In patients with hypertension, mainly severe, against the background of taking the drug, there may be an increase in blood pressure.

    Overdose:

    Specific manifestations of an overdose are not established.

    Interaction:

    The interaction of Noopept® with alcohol, hypnotics and hypotensive drugs and psychostimulating drugs has not been established.

    Special instructions:

    If it is necessary to increase the dose of the drug (up to 30 mg / day), with prolonged use, as well as with simultaneous use with other drugs, the appearance adverse reactions or worsening conditions should consult a doctor

    Effect on the ability to drive transp. cf. and fur:

    Noopept® does not affect the ability to manage machinery and vehicles.

    Form release / dosage:

    Tablets 10 mg.

    Packaging:

    For 25 tablets in a planar cell packaging made of polyvinylchloride film and aluminum foil printed lacquered.

    2 contour mesh packages together with instructions for use in a pack of cardboard.

    Storage conditions:

    In a dry, the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years. Do not use after the time specified on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:LS-001577
    Date of registration:18.07.2011 / 25.05.2015
    The owner of the registration certificate:Otisipharm, PAO Otisipharm, PAO
    Manufacturer: & nbsp
    Information update date: & nbsp14.02.16
    Illustrated instructions
      Instructions
      Up